Compare Crispr Therapeutics AG (CRSP) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Mongodb Inc — how do they compare? Crispr Therapeutics AG trades at $50.72 (market cap $4.97B), while Mongodb Inc trades at $331.95 (market cap $27.72B). The key difference: Mongodb Inc is far larger — about 5.6× Crispr Therapeutics AG's market cap, and Mongodb Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | MDB | |
|---|---|---|
Market Cap | $4.97B | $27.72B |
Sector | Health | Technology |
52-Week High | $76.78 | $440.25 |
52-Week Low | $44.34 | $201.08 |
Enterprise Value | $3.32B | $25.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
MongoDB (MDB) trades at $337.59, down 1.31% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. Revenue growth remains strong, reaching $2.01 billion in 2025, though the company is not yet profitable, posting a net loss of $129 million. Recent news highlights AI-driven demand boosting database sales, with the company raising FY2027 revenue guidance to $2.92–$2.96 billion, signaling robust growth prospects.
The outlook is positive given strong analyst support (81.8% buy ratings) and a $400.39 consensus price target, implying 18.6% upside. Key risks include ongoing losses, competitive pressures, and potential legal scrutiny from shareholder investigations. Earnings beats in recent quarters and projected narrowing losses by 2026 support a growth-oriented investment case, but profitability remains a critical watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
